2025-03-24 01:55:55
Latest Post
NCC Limited receives contract worth Rs. 1480.34 crore
IIFL Capital Services Ltd announces changes in top management
EPACK Durable Ltd receives approval for disbursement of 2nd tranche of incentive under PLI Scheme for White Goods
Ola Electric Commences Deliveries of S1 Gen 3 Scooters Across India
Raymond Ltd to invest an amount up to Rs. 65 crore in Ten X Realty East Ltd
Stock Report
Jagsonpal Pharmaceuticals Ltd Q2 FY2024-25 net profit rises to Rs. 11.45 crores
Posted On : 2024-10-24 00:43:34( TIMEZONE : IST )
Jagsonpal Pharmaceuticals Limited has reported Standalone financial results for the period ended September 30, 2024.
Financial Results (Q2 FY2025) - QoQ Comparison
The company has reported total income of Rs. 76.346 crores during the period ended September 30, 2024 as compared to Rs. 62.883 crores during the period ended June 30, 2024.
The company has posted net profit / (loss) of Rs. 11.459 crores for the period ended September 30, 2024 as against net profit / (loss) of Rs. 5.329 crores for the period ended June 30, 2024.
The company has reported EPS of Rs. 4.25 for the period ended September 30, 2024 as compared to Rs. 1.93 for the period ended June 30, 2024.
| Financials | Q2 FY2025 | Q1 FY2025 | % Change |
| Total Income | ₹76.346 crs | ₹62.883 crs |  21.41% |
| Net Profit | ₹11.459 crs | ₹5.329 crs | 115.03% |
| EPS | ₹4.25 | ₹1.93 | 120.21% |
Financial Results (Q2 FY2025) - YoY Comparison
The company has reported total income of Rs.76.346 crores during the period ended September 30, 2024 as compared to Rs.60.103 crores during the period ended September 30, 2023.
The company has posted net profit / (loss) of Rs.11.459 crores for the period ended September 30, 2024 as against net profit / (loss) of Rs.7.472 crores for the period ended September 30, 2023.
The company has reported EPS of Rs.4.25 for the period ended September 30, 2024 as compared to Rs.2.84 for the period ended September 30, 2023.
| Financials | Q2 FY2025 | Q2 FY2024 | % Change |
| Total Income | ₹76.346 crs | ₹60.103 crs | 27.03% |
| Net Profit | ₹11.459 crs | ₹7.472 crs | 53.36% |
| EPS | ₹4.25 | ₹2.84 | 49.65% |
Financial Results (Half Year Ended FY2025) - YoY Comparison
The company has reported total income of Rs.139.229 crores during the 6 Months period ended September 30, 2024 as compared to Rs.122.253 crores during the 6 Months period ended September 30, 2023.
The company has posted net profit / (loss) of Rs.16.788 crores for the 6 Months period ended September 30, 2024 as against net profit / (loss) of Rs.14.951 crores for the 6 Months period ended September 30, 2023.
The company has reported EPS of Rs.6.22 for the 6 Months period ended September 30, 2024 as compared to Rs.5.68 for the 6 Months period ended September 30, 2023.
| Financials | Half Year Ended FY2025 | Half Year Ended FY2024 | % Change |
| Total Income | ₹139.229 crs | ₹122.253 crs | 13.89% |
| Net Profit | ₹16.788 crs | ₹14.951 crs | 12.29% |
| EPS | ₹6.22 | ₹5.68 | 9.51% |
Shares of Jagsonpal Pharmaceuticals Limited was last trading in BSE at Rs. 471.35 as compared to the previous close of Rs. 459.40. The total number of shares traded during the day was 21614 in over 1458 trades.
The stock hit an intraday high of Rs. 487.50 and intraday low of 437.95. The net turnover during the day was Rs. 9952690.00.
